Peritumoral Radiomics and Predicting Treatment Response
JAMA Netw Open . 2020 Sep 1;3(9):e2016125. doi: 10.1001/jamanetworkopen.2020.16125.
Esophageal cancer is a common malignant neoplasm with a poor prognosis, causing more than 400 000 deaths worldwide every year. Neoadjuvant chemoradiotherapy (neoadjuvant CRT) followed by surgical treatment has been associated with an overall survival benefit compared with surgical treatment alone and has become a standard treatment for locally advanced esophageal cancer. Overall, approximately one-quarter to one-half of patients with esophageal cancer who receive neoadjuvant CRT will achieve pathological complete response after treatment. However, on an individual level, tumor response to neoadjuvant CRT is highly heterogenous. It has been challenging to predict the likelihood of pathological complete response for a given patient prior to treatment initiation.
Read Full Article Here: https://doi.org/10.1001/jamanetworkopen.2020.16125